Breaking News

Genmab, Lilly Enter DuoBody Platform Pact

By Kristin Brooks | January 14, 2014

To explore Genmab’s DuoBody for creation of antibodies

Genmab has entered a research collaboration with Eli Lilly and Co. for the use Genmab's DuoBody technology platform to create bispecific antibodies. Lilly will initially evaluate the DuoBody technology platform in house. Financial terms were not disclosed. 
Jan van de Winkel, Ph.D., chief executive officer of Genmab, commented, “Our DuoBody platform continues to attract strong interest from the pharmaceutical industry and we are pleased to enter our fifth partnership for this innovative bispecific antibody technology. Under this new collaboration, Lilly will evaluate the capabilities and strengths of our DuoBody platform and may consider entering a commercial license agreement if the evaluation is successful.”

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent